Ovarian Cancer Biomarkers
Increasing levels
- Increased levels of core fucosylated agalactosyl biantennary glycans and glycans containing sialyl Lewis X.
- Increased levels of tri- and tetra-antennary N-glycans.
- Increased levels of sialylated glycans and a small group of truncated glycans.
Ovarian Cancer Biomarkers
Decreasing levels
- Decreased levels of glycans containing a bisecting GlcNAc.
- Decreased levels of several neutral glycans, including high-mannose-type glycans.
References:
[14] Kim, Y. G., et al., (2009) Rapid and high-throughput analysis of N-glycans from ovarian cancer serum using a 96-well plate platform. Anal. Biochem. 391, 151–153.
[15] R. Saldova, et al., Ovarian cancer is associated with changes in glycosylation in both acute-phase proteins and IgG, Glycobiology 17 (2007) 1344.
[16] Alley, W. R., Jr., et al., (2012) N-linked glycan structures and their expressions change in the blood sera of ovarian cancer patients. J. Proteome Res. 11, 2282–2300.
[17] Kronewitter, S. R., et al., (2012) The glycolyzer: automated glycan annotation software for high performance mass spectrometry and its application to ovarian cancer glycan biomarker discovery. Proteomics 12, 2523–2538.
[18] Storr SJ, et al., The O-linked glycosylation of secretory/shed MUC1 from an advanced breast cancer patient’s serum. Glycobiology 2008, 18(6):456-462.